The divestiture of COBE CV completed

The divestiture of COBE CV completed Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that the divestiture of the cardiopulmonary care products company COBE CV has been completed. Following approval by the competition authorities, the divestiture of Gambro's subsidiary COBE CV to the Italian medical technology group Sorin Biomedica has been concluded. The divestiture results in a capital gain for Gambro of about USD 115 M (SEK 960 M). COBE CV is being deconsolidated in Gambro's accounts as of April 1, 1999. The company is based in Denver, Colorado, US, has about 950 employees, and in 1998 had a turnover of about USD 140 M (about SEK 1,150 M). For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Tim Schoenberg, Vice President, US Investor Relations Manager, +1-949-425-2185 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is the second largest provider of kidney dialysis services in the world. Gambro treats about 41,500 patients in 569 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis fluid. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion) has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/05/18/19990518BIT00020/bit0001.pdf http://www.bit.se/bitonline/1999/05/18/19990518BIT00020/bit0002.doc